Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
Kamal El Moussaoui, Othmane El Harmouchi, Aziz Baidada, Aicha Kharbach
Ballantyne syndrome or mirror syndrome was first described in 1892. It is a disorder affecting pregnant women describing the association of fetal anasarca complicated by more or less generalized maternal edema and albuminuria (and sometimes anemia). It is a rare clinical entity. Diagnosis is based on a triad consisting of fetal hydrops, generalized maternal edema and placentomegaly. It can be associated with fetal hydrops from any cause. Diagnostic should be suspected in patients with maternal edema syndrome associated with fetal anasarca...
2021: Pan African Medical Journal
#22
JOURNAL ARTICLE
Adam J Nelson, Rishi Puri, Danielle M Brennan, Todd J Anderson, Leslie Cho, Christie M Ballantyne, John Jp Kastelein, Wolfgang Koenig, Helina Kassahun, Ransi M Somaratne, Scott M Wasserman, Steven E Nissen, Stephen J Nicholls
Objective: On-treatment levels of high sensitivity C-reactive protein (hsCRP) in statin-treated patients predict plaque progression and the prospective risk of atherosclerotic cardiovascular events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors produce additional LDL-C lowering, reduce plaque burden and improve cardiovascular outcomes in statin-treated patients. It is unknown whether residual systemic inflammation attenuates their favorable effects on plaque burden...
September 2020: American journal of preventive cardiology
#23
Erinna Mohamad Zon, Nik Ahmad Zuky Nik Lah, Pek Sung Hoo
Mirror syndrome is a rare clinical condition in pregnancy associated with significant fetal mortality and maternal morbidity. It is characterized by a triad of complications: fetal hydrops, placenta oedema, and maternal oedema. We are reporting one case of late-onset Mirror syndrome in which the patient presented later in the gestation of 36 weeks due to excessive weight gain and clinical sign mimicking preeclampsia. Awareness of this disease is essential, as a failure of recognition will delay the treatment and cause higher maternal and perinatal morbidity and mortality...
March 25, 2021: Malaysian Family Physician
#24
REVIEW
Ayssa Teles Abrao Trad, Ricardo Czeresnia, Amro Elrefaei, Eniola R Ibirogba, Kavita Narang, Rodrigo Ruano
INTRODUCTION: Mirror syndrome is a rare disease associated with high fetal mortality of up to 67.2%. It is thought to be underdiagnosed and is often associated with preeclampsia. Mirror syndrome is characterized by "triple edema": generalized maternal, placental, and fetal edema. OBJECTIVE: This comprehensive review aims to thoroughly summarize the existing data and provide a broad update on the topic to help accurate diagnosis and encourage further research. METHODS: A comprehensive search of several databases (Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, and Daily, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus) was conducted...
October 2022: Journal of Maternal-fetal & Neonatal Medicine
#25
JOURNAL ARTICLE
Ali M Agha, Christie M Ballantyne
No abstract text is available yet for this article.
September 30, 2020: European Journal of Preventive Cardiology
#26
REVIEW
Chayakrit Krittanawong, Anirudh Kumar, Joshua Hahn, Zhen Wang, Hong Ju Zhang, Tao Sun, Biykem Bozkurt, Christie M Ballantyne, Salim S Virani, Jonathan L Halperin, Hani Jneid
In December 2019, an unprecedented outbreak of pneumonia cases associated with acute respiratory distress syndrome (ARDS) first occurred in Wuhan, Hubei Province, China. The disease, later named Coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO), was caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), and on January 30, 2020, the WHO declared the outbreak of COVID-19 to be a public health emergency. COVID-19 is now a global pandemic impacting more than 43,438,043 patients with 1,158,596 deaths globally as of August 26th, 2020...
2020: American Journal of Cardiovascular Disease
#27
JOURNAL ARTICLE
Zeqin Lian, Anum Saeed, Xueying Peng, Xiaoyuan Dai Perrard, Xiaoming Jia, Aliza Hussain, Christie M Ballantyne, Huaizhu Wu
BACKGROUND: Accumulation of lipoprotein X (LpX) in blood can cause severe hypercholesterolemia and cutaneous xanthomas. Monocytes sensitively sense lipid changes in circulation and contribute to inflammation. However, how monocytes respond to LpX is undefined. OBJECTIVE: We examined the phenotype of monocytes from a patient, who had LpX, severe hypercholesterolemia, and extensive cutaneous xanthomas, and effects of semiselective plasmapheresis therapy (SPPT). METHOD: Fluorescence-activated cell sorting and adhesion assays were used to examine monocyte phenotype and ex vivo oxidized low-density lipoprotein uptake and adhesion in the patient before and after treatment with SPPT...
September 4, 2020: Journal of Clinical Lipidology
#28
JOURNAL ARTICLE
Roberta Florido, Lucia Kwak, Mariana Lazo, Erin D Michos, Vijay Nambi, Roger S Blumenthal, Gary Gerstenblith, Priya Palta, Stuart D Russell, Christie M Ballantyne, Elizabeth Selvin, Aaron R Folsom, Josef Coresh, Chiadi E Ndumele
Background Greater physical activity (PA) is associated with lower heart failure (HF) risk. However, it is unclear whether this inverse association exists across all subgroups at high risk for HF, particularly among those with preexisting atherosclerotic cardiovascular disease. Methods and Results We followed 13 810 ARIC (Atherosclerosis Risk in Communities) study participants (mean age 55 years, 54% women, 26% black) without HF at baseline (visit 1; 1987-1989). PA was assessed using a modified Baecke questionnaire and categorized according to American Heart Association guidelines: recommended, intermediate, or poor...
May 11, 2020: Journal of the American Heart Association
#29
JOURNAL ARTICLE
Gregory G Schwartz, Lawrence A Leiter, Christie M Ballantyne, Philip J Barter, Donald M Black, David Kallend, Fouzia Laghrissi-Thode, Eran Leitersdorf, John J V McMurray, Stephen J Nicholls, Anders G Olsson, David Preiss, Prediman K Shah, Jean-Claude Tardif, John Kittelson
OBJECTIVE: Incident type 2 diabetes is common among patients with recent acute coronary syndrome and is associated with an adverse prognosis. Some data suggest that cholesteryl ester transfer protein (CETP) inhibitors reduce incident type 2 diabetes. We compared the effect of treatment with the CETP inhibitor dalcetrapib or placebo on incident diabetes in patients with recent acute coronary syndrome. RESEARCH DESIGN AND METHODS: In the dal-OUTCOMES trial, 15,871 patients were randomly assigned to treatment with dalcetrapib, 600 mg daily, or placebo, beginning 4-12 weeks after an acute coronary syndrome...
March 6, 2020: Diabetes Care
#30
JOURNAL ARTICLE
Taufiq Salahuddin, John Kittelson, Jean-Claude Tardif, Prediman K Shah, Anders G Olsson, Stephen J Nicholls, Eran Leitersdorf, Lawrence A Leiter, David Kallend, Donald M Black, Philip J Barter, Christie M Ballantyne, Gregory G Schwartz
BACKGROUND: High-density lipoprotein cholesterol (HDL-C) concentration is inversely related to risk of major adverse cardiovascular events (MACE) in epidemiologic studies but is a poorer predictor of MACE in patients with established coronary heart disease. HDL particle concentration (HDLP) has been proposed as a better predictor of risk. We investigated whether HDLP is associated with risk of MACE after acute coronary syndrome (ACS). METHODS: The dal-Outcomes trial compared the CETP inhibitor dalcetrapib with placebo in patients with recent ACS...
March 2020: American Heart Journal
#31
JOURNAL ARTICLE
Nathan D Wong, Ezra A Amsterdam, Christie Ballantyne, Amit Khera, Khurram Nasir, Peter P Toth
The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol retains focus on recommendations for statin treatment in the original four statin-eligible groups [those with atherosclerotic cardiovascular disease (ASCVD), diabetes, low-density lipoprotein cholesterol (LDL-C) ≥ 190 mg/dL, and higher risk primary prevention] without the use of treatment initiation or target LDL-C levels from the earlier 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline, but has several new features...
February 2020: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
#32
Caroline Ruth Mathias, Carmela Rizvi
Mirror syndrome, also called Ballantyne syndrome, is a rare condition in pregnancy, defined by the presence of the clinical triad of fetal hydrops, placentomegaly and maternal oedema. Any aetiology of fetal hydrops, including rhesus iso-immunization, congenital infection, twin-to-twin transfusion, structural anomalies and fetal malignancies, can lead to the syndrome. The pathogenesis, although not well established, mimics trophoblastic damage and maternal vascular endothelial dysfunction, as is also seen in pre-eclampsia, and, hence, the two conditions may have a similar clinical presentation...
July 2019: Case Reports in Women's Health
#33
Silvia F Navarro-Perez, Karen Corona-Fernandez, José L Rodriguez-Chavez, A Bañuelos-Franco, María G Zavala-Cerna
Ballantyne syndrome (BS) also called mirror syndrome is defined by the presence of a clinical triad that includes fetal hydrops and placental and maternal edema. Here we present a clinical case of a 34-year-old woman with a 29 weeks' pregnancy, who developed BS and fetal loss probably due to failure in prompt recognition of a rapidly growing sacrococcygeal teratoma (SCT). Due to similarities in clinical presentation with preeclampsia and the importance in early identification of the source for BS, we underwent a literature review in order to identify significant signs and symptoms, as well as sonographic changes, in order to help clinicians to make this prompt recognition, identification of the cause, and early management of BS, which will have an important impact in maternal and fetal survival...
2019: Case Reports in Obstetrics and Gynecology
#34
JOURNAL ARTICLE
Riyaz Patel, Vinicius Tragante, Amand F Schmidt, Raymond O McCubrey, Michael V Holmes, Laurence J Howe, Kenan Direk, Axel Åkerblom, Karin Leander, Salim S Virani, Karol A Kaminski, Jochen D Muehlschlegel, Hooman Allayee, Peter Almgren, Maris Alver, Ekaterina V Baranova, Hassan Behlouli, Bram Boeckx, Peter S Braund, Lutz P Breitling, Graciela Delgado, Nubia E Duarte, Marie-Pierre Dubé, Line Dufresne, Niclas Eriksson, Luisa Foco, Markus Scholz, Crystel M Gijsberts, Charlotte Glinge, Yan Gong, Jaana Hartiala, Mahyar Heydarpour, Jaroslav A Hubacek, Marcus Kleber, Daniel Kofink, Salma Kotti, Pekka Kuukasjärvi, Vei-Vei Lee, Andreas Leiherer, Petra A Lenzini, Daniel Levin, Leo-Pekka Lyytikäinen, Nicola Martinelli, Ute Mons, Christopher P Nelson, Kjell Nikus, Anna P Pilbrow, Rafal Ploski, Yan V Sun, Michael W T Tanck, W H Wilson Tang, Stella Trompet, Sander W van der Laan, Jessica Van Setten, Ragnar O Vilmundarson, Chiara Viviani Anselmi, Efthymia Vlachopoulou, Lawien Al Ali, Eric Boerwinkle, Carlo Briguori, John F Carlquist, Kathryn F Carruthers, Gavino Casu, John Deanfield, Panos Deloukas, Frank Dudbridge, Thomas Engström, Natalie Fitzpatrick, Kim Fox, Bruna Gigante, Stefan James, Marja-Liisa Lokki, Paulo A Lotufo, Nicola Marziliano, Ify R Mordi, Joseph B Muhlestein, Christopher Newton-Cheh, Jan Pitha, Christoph H Saely, Ayman Samman-Tahhan, Pratik B Sandesara, Andrej Teren, Adam Timmis, Frans Van de Werf, Els Wauters, Arthur A M Wilde, Ian Ford, David J Stott, Ale Algra, Maria G Andreassi, Diego Ardissino, Benoit J Arsenault, Christie M Ballantyne, Thomas O Bergmeijer, Connie R Bezzina, Simon C Body, Eric H Boersma, Peter Bogaty, Michiel Bots, Hermann Brenner, Jasper J Brugts, Ralph Burkhardt, Clara Carpeggiani, Gianluigi Condorelli, Rhonda M Cooper-DeHoff, Sharon Cresci, Nicolas Danchin, Ulf de Faire, Robert N Doughty, Heinz Drexel, James C Engert, Keith A A Fox, Domenico Girelli, Diederick E Grobbee, Emil Hagström, Stanley L Hazen, Claes Held, Harry Hemingway, Imo E Hoefer, G Kees Hovingh, Reza Jabbari, Julie A Johnson, J Wouter Jukema, Marcin P Kaczor, Mika Kähönen, Jiri Kettner, Marek Kiliszek, Olaf H Klungel, Bo Lagerqvist, Diether Lambrechts, Jari O Laurikka, Terho Lehtimäki, Daniel Lindholm, B K Mahmoodi, Anke H Maitland-van der Zee, Ruth McPherson, Olle Melander, Andres Metspalu, Anna Niemcunowicz-Janica, Oliviero Olivieri, Grzegorz Opolski, Colin N Palmer, Gerard Pasterkamp, Carl J Pepine, Alexandre C Pereira, Louise Pilote, Arshed A Quyyumi, A Mark Richards, Marek Sanak, Agneta Siegbahn, Tabassome Simon, Juha Sinisalo, J Gustav Smith, John A Spertus, Steen Stender, Alexandre F R Stewart, Wojciech Szczeklik, Anna Szpakowicz, Jean-Claude Tardif, Jurriën M Ten Berg, Jacob Tfelt-Hansen, George Thanassoulis, Joachim Thiery, Christian Torp-Pedersen, Yolanda van der Graaf, Frank L J Visseren, Johannes Waltenberger, Peter E Weeke, Pim Van der Harst, Chim C Lang, Naveed Sattar, Vicky A Cameron, Jeffrey L Anderson, James M Brophy, Guillaume Paré, Benjamin D Horne, Winfried März, Lars Wallentin, Nilesh J Samani, Aroon D Hingorani, Folkert W Asselbergs
BACKGROUND: The "GENetIcs of sUbSequent Coronary Heart Disease" (GENIUS-CHD) consortium was established to facilitate discovery and validation of genetic variants and biomarkers for risk of subsequent CHD events, in individuals with established CHD. METHODS: The consortium currently includes 57 studies from 18 countries, recruiting 185,614 participants with either acute coronary syndrome, stable CHD or a mixture of both at baseline. All studies collected biological samples and followed-up study participants prospectively for subsequent events...
March 21, 2019: Circulation. Genomic and Precision Medicine
#35
JOURNAL ARTICLE
Sebastian Rupert Hobson, Euan Morrison Wallace, Yuen Fu Chan, Andrew Grant Edwards, Mark Wui Tee Teoh, Andrea Phaik-Leng Khaw
Objectives: The purpose of this article was to further elucidate the pathophysiology of Mirror (Ballantyne) syndrome within the context of known biomarkers for preeclampsia. Methods: This novel insight from clinical practice involved a case of post-twin-to-twin transfusion syndrome-laser hydrops in an ex-donor twin, corroborated by histopathologic placental territory edema and maternal sequelae of Mirror syndrome. We serially measured the levels of activin A, follistatin, endothelin-1 (ET-1), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), soluble fms-like tyrosine kinase 1 (sFlt), and von Willebrand factor (vWF) in the maternal serum from disease evolution through to recovery...
March 2020: Journal of Maternal-fetal & Neonatal Medicine
#36
LETTER
Salim S Virani, Julia M Akeroyd, Vijay Nambi, Erin D Michos, Pamela B Morris, Khurram Nasir, Sidney C Smith, Neil J Stone, Laura A Petersen, Christie M Ballantyne
No abstract text is available yet for this article.
January 15, 2019: Circulation
#37
REVIEW
Fatima El Mangoub, Rachid Ait Bouhou, Zakaria Idri, Jaouad Kouach, Khalid Guelzim, Driss Moussaoui Rahali
Ballantyne syndrome or preeclampsia (Mirror syndrome) is a rare clinical entity. Ethiopathogenesis is still poorly elucidated. Diagnosis must be suspected in patients with maternal edematous syndrome associated with fetal anasarca. Guarded fetal prognosis can be associate with strong maternal morbidity. This highlights the role of early diagnosis based on cause detection aimed to establish an antenatal treatment that could improve maternofoetal prognosis. We report and discuss in the light of a literature review a case of a probable Ballantyne syndrome secondary to fetal malformative syndrome complicated by eclampsia in the mother...
2018: Pan African Medical Journal
#38
JOURNAL ARTICLE
Stephen J Nicholls, Rishi Puri, Christie M Ballantyne, J Wouter Jukema, John J P Kastelein, Wolfgang Koenig, R Scott Wright, David Kallend, Peter Wijngaard, Marilyn Borgman, Kathy Wolski, Steven E Nissen
Importance: Infusing a high-density lipoprotein mimetic containing apolipoprotein A-I Milano demonstrated potential atheroma regression in patients following an acute coronary syndrome. To our knowledge, the effect of infusing a new mimetic preparation (MDCO-216) with contemporary statin therapy is unknown. Objective: To determine the effect of infusing MDCO-216 on coronary atherosclerosis progression. Design, Setting, and Participants: This double-blind, randomized clinical trial conducted in 22 hospitals in Canada and Europe compared the effects of 5 weekly intravenous infusions of MDCO-216 at a dose of 20 mg/kg weekly (n = 59) with placebo (n = 67) in statin-treated patients with an acute coronary syndrome...
September 1, 2018: JAMA Cardiology
#39
Amanda Grant-Orser, Brennan Ballantyne, Wael Haddara
A 68-year-old male presented to the emergency department with retrosternal chest pain, presyncope, and then a pulseless electrical activity cardiac arrest. An ECG prior to his arrest revealed ST elevations in leads V1-V3, Q waves in lead V2, and reciprocal ST depressions in the lateral and inferior leads. He received thrombolytic therapy for a presumptive diagnosis of ST elevation myocardial infarction. Return of spontaneous circulation was achieved and he underwent a coronary angiogram. No critical disease was found and his left ventriculogram showed normal contraction...
2018: Case Reports in Critical Care
#40
JOURNAL ARTICLE
Gregory G Schwartz, Christie M Ballantyne, Philip J Barter, David Kallend, Lawrence A Leiter, Eran Leitersdorf, John J V McMurray, Stephen J Nicholls, Anders G Olsson, Prediman K Shah, Jean-Claude Tardif, John Kittelson
Importance: It is uncertain whether lipoprotein(a) [Lp(a)], which is associated with incident cardiovascular disease, is an independent risk factor for recurrent cardiovascular events after acute coronary syndrome (ACS). Objective: To determine the association of Lp(a) concentration measured after ACS with the subsequent risk of ischemic cardiovascular events. Design, Setting, and Participants: This nested case-cohort analysis was performed as an ad hoc analysis of the dal-Outcomes randomized clinical trial...
February 1, 2018: JAMA Cardiology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
